Загрузка...
An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma
We conducted a phase 1/2 trial evaluating the combination of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone (CVDD) for newly diagnosed multiple myeloma (MM). The primary objective of the phase 1 was to evaluate the safety and tolerability of maximum planned dose (MP...
Сохранить в:
| Опубликовано в: : | Eur J Haematol |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4508238/ https://ncbi.nlm.nih.gov/pubmed/25600676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.12509 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|